BMC PUBLIC HEALTH 11/03/21 Socio-economic drivers of drug-resistant tuberculosis in Africa: a scoping review. 1.Cramm JM, Finkenflügel HJM, Møller V, Nieboer AP.
TB treatment initiation and adherence in a south African community influenced more by perceptions than by knowledge of tuberculosis. BMC Public Health. 2010;10(1):72.Article Google Scholar 2.Mcnally TW, De Wildt G, Meza G, Wiskin CMD. Improving outcomes for multi-drug-resistant tuberculosis in the Peruvian Amazon–a qualitative study exploring the experiences and perceptions of patients and healthcare professionals.
BMC Health Serv Res. 2019;19(1):594.Article Google Scholar 3.World Health Organisation. Global tuberculosis report 2018. Rev. Soc. Bras. Med. Trop. vol.54 Uberaba 2021 Epub Mar 22, 2021 Drug-Resistant Mycobacterium tuberculosis Isolates from New and Previously Treated TB Patients in China, 2017-2019. Tuberculosis (TB), usually caused by Mycobacterium tuberculosis (MTB), remains a major threat to the public health worldwide.
Although the directly observed treatment, short-course (DOTS) strategy has significantly reduced the incidence of TB in recent years, the emergence of drug-resistant TB has severely hampered TB prevention and control, especially regarding multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB)1. TB epidemics are unevenly distributed in China, and there is a high prevalence in rural areas, especially those that are underdeveloped in the northwest and southwest of China1. Migration, primarily from rural to urban environments, has become common in China in recent decades.
Internal migration presents a significant challenge to the national TB control strategies. The latest national survey revealed that the frequency of MDR-TB among pulmonary TB patients in China was 8.32%1. Communicable Diseases Intelligence - OCT 2020 - Retrospective analysis of multidrug-resistant tuberculosis case notifications in Australia (1999–2018) EUREKALERT 18/11/20 Solving a mystery: How the TB bacterium develops rapid resistance to antibiotics. For a slow-growing microbe that multiplies infrequently, Mycobacterium tuberculosis, the pathogen that causes tuberculosis (TB) has long puzzled researchers as to how it develops resistance to antibiotics so quickly, in a matter of weeks to months.
Now, TB researchers at San Diego State University have uncovered a crucial clue to the mystery: the answer may lie in the epigenetic domain rather than the genetic domain where most scientists have concentrated their efforts. Their discovery could help advance new diagnostics, therapeutics and vaccine targets. Epigenetics is the study of inheritable changes in gene expression that do not involve a corresponding change to the underlying DNA sequence -- meaning changes to the phenotype but no change in the genotype. This affects only the physical structure of the DNA, through a process called DNA methylation where a chemical 'cap' is added to the DNA molecule, preventing or facilitating the expression of certain genes.
Sci Rep. 2019 Mar 14;9(1):4425. A new oligonucleotide array for the detection of multidrug and extensively drug-resistance tuberculosis. Because of the urgent need to rapidly and accurately diagnose drug-resistant TB, the WHO has recommended the GenoType MTBDRplus and GenoType MTBDRsl tests for detecting resistance to first- and second-line drugs1.
We developed an oligonucleotide array consisting of 60 mutant probes for detecting resistance to 8 anti-TB drugs in 6 to 7 hours. The sensitivity and specificity of the array were comparable to those of the WHO-recommended GenoType MTBDRplus (91.3% and 98.0% for RIF; 89.4% and 98.9 for INH), the GenoType MTBDRsl tests (94.8% and 98.% for FQs; 83.0–91.3% and 94.3–100% for SLIDs), the AID TB resistance LPA (AID Diagnostika, Germany) (100% and 100% for RIF; 97.8% and 100% for INH; 60.0% and 91.7% for EMB; 100% and 96.6% for SM; 33.3% and 98.1% for FQs; 100% and 100% for SLIDs), the Nipro NTM/MDRTB detection kit (Nipro, Japan) (92.4% and 97.5% for RIF; 89.9% and 99.4% for INH) and the Xpert MTB/RIF Ultra (Cepheid, USA)(92.7% and 98.0% for RIF)6,26,27,28,29. CDC EID - MARS 2020 - Multidrug- and Extensively Drug-Resistant Mycobacterium tuberculosis Beijing Clades, Ukraine, 2015.
Disclaimer: Early release articles are not considered as final versions.
Any changes will be reflected in the online version in the month the article is officially released. Matthias Merker. THE LANCET 01/08/19 Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Introduction Tuberculosis is the infectious disease responsible for the most deaths worldwide.
The complex natural history of Mycobacterium tuberculosis means that, for ultimate disease control, people with latent infections need to be targeted. WHOTargets: the END TB strategy and the Stop TB strategy. NATURE 13/05/19 GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions. CDC EID - MARS 2019 - Response to Isoniazid-Resistant Tuberculosis in Homeless Shelters, Georgia, USA, 2015–2017. David P.
Holland , Shanica Alexander, Udodirim Onwubiko, Neela D. Goswami, Aliya Yamin, Omar Mohamed, Rose-Marie Sales, Gail Grant, Phillip Talboy, Susan Ray, and Kathleen E. Toomey Author affiliations: Fulton County Board of Health, Atlanta, Georgia, USA (D.P. Suggested citation for this article Abstract. CDC EID - MARS 2019 - Longitudinal Outbreak of Multidrug-Resistant Tuberculosis in a Hospital Setting, Serbia.
Irena Arandjelović1 , Matthias Merker1, Elvira Richter, Thomas A.
Kohl, Branislava Savić, Ivan Soldatović, Thierry Wirth, Dragana Vuković1, and Stefan Niemann1. CDC EID - NOV 2018 - Outbreak of Tuberculosis and Multidrug-Resistant Tuberculosis, Mbuji-Mayi Central Prison, Democratic Republic of the Congo. BMC PUBLIC HEALTH 14/09/18 Risk factors for multidrug-resistant tuberculosis among tuberculosis patients in Serbia: a case-control study.
Although, Serbia is not a high MDR-TB burden country the study has provided baseline information about factors associated with MDR-TB which can support implementation of targeted interventions to decrease number of cases with MDR-TB.
Among socio-demographic factors, we identified that monthly income of the family ≤100 Euro is a risk factor for development of MDR-TB. It means that cases with lower income had almost four times higher risk of developing MDR-TB than controls. In almost 50% of cases, monthly income of the family of MDR TB cases was equal to level of poverty for Serbia, significantly lower than the corresponding general population . These data are alarming given the circumstances that country does not allocate funds for social welfare payments for these patients. THE LANCET 22/03/18 Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.
GERMAN CENTRE FOR INFECTION RESEARCH 10/01/18 Improved prediction of tuberculosis bacteria resistance. 10 January 2018 - PRESS RELEASE An international tuberculosis consortium—including the Research Center Borstel—has succeeded in developing a standardised and internationally recognised method that is able to better predict in tuberculosis bacteria resistance in future.
Their findings were published in the European Respiratory Journal. GERMAN CENTRE FOR INFECTION RESEARCH 15/01/18 Genome analysis confirms Europe-wide multidrug-resistant tuberculosis outbreak. 15 January 2018 - PRESS RELEASE The National Reference Center at the Research Center Borstel has confirmed a Europe-wide outbreak of a multidrug-resistant Mycobacterium tuberculosis strain in 29 refugees from the Horn of Africa.
The Research Center Borstel as well as the European Centre for Disease Prevention and Control, the Robert Koch Institute and the University of Zurich’s National Reference Center for Mycobacteria were involved in the coordination of this Europe-wide investigation. The results have now been published in the renowned journal The Lancet Infectious Diseases. The outbreak strain could be conclusively confirmed by genome analysis© DZIF/scienceRELATIONS In 2016, the National Reference Center for Mycobacteria (NRZ) in Borstel and in Switzerland (NZM) identified a previously unknown tuberculosis pathogen almost simultaneously.
GERMAN CENTRE FOR INFECTION RESEARCH 12/03/18 Disparities in treatment of multidrug-resistant tuberculosis across Europe. 12 March 2018 - PRESS RELEASE Scientists have shown that multidrug-resistant tuberculosis care in Eastern Europe is markedly worse than in Western Europe. Multi-layered images of lungs help diagnosis and therapy.© FZ Borstel. Int J Mycobacteriol. 2017 Apr-Jun;6(2):156-161. Characterization of pyrazinamide resistance in consecutive multidrug-resistant mycobacterium tuberculosis isolates in sweden between 2003 and 2015. Characterization of pyrazinamide resistance in consecutive multidrug-resistant mycobacterium tuberculosis isolates in sweden between 2003 and 2015 Mikael Mansjo1, Jim Werngren1, Sven Hoffner2 1 Department of Microbiology, Public Health Agency of , Solna, Sweden2 Department of Microbiology, Public Health Agency of ; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden Correspondence Address:Mikael MansjoDepartment of Microbiology, Public Health Agency of Sweden, Solna Sweden Source of Support: None, Conflict of Interest: None DOI: 10.4103/ijmy.ijmy_23_17.
EUROSURVEILLANCE 23/11/17 Childhood multidrug-resistant tuberculosis in the European Union and European Economic Area: an analysis of tuberculosis surveillance data from 2007 to 2015. CDC EID - NOV 2017 - Drug-Resistant Tuberculosis among Children, China, 2006–2015. Author affiliations: Shandong Provincial Hospital affiliated with Shandong University, Jinan, China (N. -N. Tao, Y. EUROSURVEILLANCE 12/01/17 A joint cross-border investigation of a cluster of multidrug-resistant tuberculosis in Austria, Romania and Germany in 2014 using classic, genotyping and whole genome sequencing methods: lessons learnt.
Int J Tuberc Lung Dis. 2016 Apr;20(4):448-55. Use of Xpert(®) MTB/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan. CLINICAL MICROBIOLOGY AND INFECTION 10/12/16 Novel rapid PCR for the detection of Ile491Phe rpoB mutation of Mycobacterium tuberculosis, a rifampicin resistance-conferring mutation undetected by commercial assays. Am J Trop Med Hyg 2016 16-0120 Rapid Detection of Mycobacterium tuberculosis Strains Resistant to Isoniazid and/or Rifampicin: Standardization of Multiplex Polymerase Chain Reaction Analysis. + Author Affiliations + Author Notes Financial support: This study was funded by the Belgian Directorate-General for Development Cooperation (DGDC) through an institutional collaboration between the Institute of Tropical Medicine in Antwerp, Belgium, and the Instituto de Medicina Tropical Alexander von Humboldt in Lima, Peru.
PARLEMENT EUROPEEN - Réponse à question E-007826-15 Drug-resistant TB and immigration. IDW 02/02/16 Extrem resistenter Tuberkulose-Erreger entwickelt weitere Resistenzen gegen neue Antibiotika. Extrem resistenter Tuberkulose-Erreger entwickelt weitere Resistenzen gegen neue Antibiotika Ergänzung vom 02.02.2016 Wissenschaftlerinnen und Wissenschaftlern unter Leitung des Leibniz Forschungszentrums Borstel, des Instituts für Mikrobiologie und Laboratoriumsdiagnostik in Gauting, des Instituts für Medizinische Mikrobiologie der Universität Zürich und des Deutschen Zentrums für Infektionsforschung (DZIF) haben bei einem Tuberkulose-Patienten zum erstem Mal einen extrem resistenten Mycobacterium tuberculosis Stamm mit zusätzlichen Resistenzen gegenüber den neuen Antibiotika Delamanid und Bedaquilin nachgewiesen.
CDC EID – NOV 2015 – Au sommaire notamment: Epidemiology of Primary Multidrug-Resistant Tuberculosis, Vladimir Region, Russia ; Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.V. Ershova, D.A. Kaminski, J.P. INTECH - FEV 2012 - Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance. EUROSURVEILLANCE 17/10/13 Au sommaire:Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 20.
Documents OMS. Documents CDC. The worldwide epidemic of multidrug-resistant tuberculosis : The Lancet Infectious Diseases. WHO estimates that a third of the world's population is infected with Mycobacterium tuberculosis. In 2009, there were almost 9 million new cases of tuberculosis and the disease killed almost 1 million people around the world. Since the discovery of the BCG vaccine, and the development of new antibiotics in the 1950s, the incidence of tuberculosis has fallen substantially. From 1995 to 2009, about 49 million people received treatment for the disease, 41 million of whom were cured, saving up to 6 million. However, multidrug-resistant (MDR) tuberculosis—ie, resistance to two of the most potent drugs, rifampicin and isoniazid—threatens to turn the tide against the medical advances of the past century. PLOS 16/06/11 Dynamics of Antibiotic Resistant Mycobacterium tuberculosis during Long-Term Infection and Antibiotic Treatment.
For an infecting bacterium the human body provides several potential ecological niches with both internally (e.g. host immunity) and externally (e.g. antibiotic use) imposed growth restrictions that are expected to drive adaptive evolution in the bacterium, including the development of antibiotic resistance. To determine the extent and pattern of heterogeneity generated in a bacterial population during long-term antibiotic treatment, we examined in a monoclonal Mycobacterium tuberculosis infection antibiotic resistant mutants isolated from one patient during a 9-years period. There was a progressive accumulation of resistance mutations in the infecting clone. Furthermore, apparent clonal sweeps as well as co-existence of different resistant mutants were observed during this time, demonstrating that during treatment there is a high degree of dynamics in the bacterial population.
Tuberculose humaine. Extensively drug-resistant tuberculosis. THE ROYAL SOCIETY - 2001 - Will tuberculosis become resistant to all antibiotics? SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL - 2008 - Thèse en ligne:Molecular characterisation of antibioticresistance in M. The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis. Schweiz Med Wochenschr 2000;130:1909–13 Drug-resistant tuberculosis: resistance mechanisms and rapid susceptibility testing. Database study of antibiotic resistant tuberculosis in the United Kingdom, 1994-6. The global increase in tuberculosis which has occurred in the 1980s and 1990s, and the associated re-emergence of resistance to antituberculous drugs, has focused attention on recent trends in resistance in Europe and the United States.1–3 In the United Kingdom overall drug resistance levels have been low.4 A surveillance system, the UK Mycobacterial Resistance Network (MYCOBNET), was established in 1994 by the Public Health Laboratory Service to record drug resistance in laboratory isolates of tuberculosis.
We used data from this network to examine resistance among people with newly diagnosed tuberculosis. Subjects, methods, and results We analysed the data on initial isolates of Mycobacterium tuberculosis complex referred to United Kingdom reference laboratories5 during 1994 to 1996. Initial isolates were defined as the first positive culture from a person from whom no positive culture had been recorded during the past 12 months. Comment Acknowledgments. INSTITUTE OF MEDICINE - APRIL 2011 - The New Profile of Drug-Resistant Tuberculosis in Russia - Summary of a Workshop.
Pharmaceuticals 2010, 3, 2268-2290 Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial.